Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan, Fludarabine, and TBI for Non-Myeloablative Allo-HSCT
NCT00245037Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2005
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML) and 7 more, sponsored by OHSU Knight Cancer Institute. Primary endpoints: Regimen-Related Toxicities and Non-relapse Mortality. Started Jun 2005; status: completed.
02
Drugs
busulfan
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)chronic lymphocytic leukemia (CLL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00245037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00245037.